Inventor · disambiguated record
David R. Lancia, Jr.
Also filed as: LANCIA DAVID R · LANCIA JR DAVID · LANCIA JR DAVID R
113 granted patents·18 pending applications·1,184 citations·filing 2014–2024
99Inventor score
Files withFORMA THERAPEUTICS INC88VALO HEALTH INC16VALO EARLY DISCOVERY INC13FORMA TM2 INC7NOVO NORDISK HEALTHCARE AG6
Top patents by PatentIndex Score
131 records- 0199US10829461B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 10, 2020·15 cites·12 claims
- 0299US10829462B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 10, 2020·15 cites·17 claims
- 0399US10377726B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·22 cites·10 claims
- 0499US10112915B23-aryl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Oct 30, 2018·41 cites·31 claims
- 0598US11279681B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Mar 22, 2022·6 cites·20 claims
- 0698US10822316B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Nov 3, 2020·10 cites·15 claims
- 0798US10550098B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·17 cites·25 claims
- 0898US10494354B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·17 claims
- 0998US10494353B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·17 cites·12 claims
- 1098US10472371B2Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 12, 2019·13 cites·3 claims
- 1198US10472337B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 12, 2019·17 cites·12 claims
- 1298US10428031B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 1, 2019·15 cites·20 claims
- 1398US10421731B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·15 cites·19 claims
- 1498US10421732B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 24, 2019·16 cites·13 claims
- 1598US10414752B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·19 cites·20 claims
- 1698US10414738B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·16 cites·20 claims
- 1798US10239845B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Mar 26, 2019·25 cites·42 claims
- 1898US10214501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·38 claims
- 1998US10214500B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Feb 26, 2019·20 cites·35 claims
- 2098US10208052B1Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2018·Granted Feb 19, 2019·36 cites·10 claims
- 2198US9834539B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Dec 5, 2017·28 cites·108 claims
- 2298US9630922B23-spiro-7-hydroxamic acid tetralins as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Apr 25, 2017·49 cites·33 claims
- 2398US9624175B2Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·25 cites·39 claims
- 2498US9624216B2Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·26 cites·74 claims
- 2597US11980611B2Treating sickle cell disease with a pyruvate kinase R activating compoundNOVO NORDISK HEALTHCARE AG·Filed 2022·Granted May 14, 2024·3 cites·4 claims
- 2697US11844787B2Activating pyruvate kinase RNOVO NORDISK HEALTHCARE AG·Filed 2021·Granted Dec 19, 2023·5 cites·4 claims
- 2797US11702412B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsVALO HEALTH INC·Filed 2020·Granted Jul 18, 2023·4 cites·18 claims
- 2897US11649242B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsFORMA THERAPEUTICS INC·Filed 2021·Granted May 16, 2023·5 cites·4 claims
- 2997US11498913B2Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2020·Granted Nov 15, 2022·4 cites·18 claims
- 3097US11396513B2Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2020·Granted Jul 26, 2022·6 cites·8 claims
- 3197US11071725B2Activating pyruvate kinase RFORMA THERAPEUTICS INC·Filed 2020·Granted Jul 27, 2021·8 cites·21 claims
- 3297US10988450B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Apr 27, 2021·6 cites·14 claims
- 3397US10675274B2Activating pyruvate kinase RFORMA THERAPEUTICS INC·Filed 2019·Granted Jun 9, 2020·12 cites·13 claims
- 3497US10513501B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 24, 2019·11 cites·20 claims
- 3597US10494352B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 3697US10494351B23-aryl-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Dec 3, 2019·12 cites·20 claims
- 3797US10464910B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·15 claims
- 3897US10464909B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·12 cites·17 claims
- 3997US10457652B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 29, 2019·12 cites·18 claims
- 4097US10450283B23-alkyl bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·16 claims
- 4197US10450284B23-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 22, 2019·14 cites·13 claims
- 4297US10442776B23-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Oct 15, 2019·15 cites·18 claims
- 4397US10183934B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Jan 22, 2019·27 cites·28 claims
- 4497US9840491B2Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted Dec 12, 2017·22 cites·17 claims
- 4597US9771349B2Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitorsFORMA THERAPEUTICS INC·Filed 2015·Granted Sep 26, 2017·27 cites·68 claims
- 4697US9637453B23-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2016·Granted May 2, 2017·51 cites·31 claims
- 4796US11014927B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsFORMA THERAPEUTICS INC·Filed 2018·Granted May 25, 2021·6 cites·3 claims
- 4896US10836771B2Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 17, 2020·7 cites·2 claims
- 4996US10407418B2Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Sep 10, 2019·16 cites·19 claims
- 5096US10377767B2Thienopyrimidinones as ubiquitin-specific protease 7 inhibitorsFORMA THERAPEUTICS INC·Filed 2018·Granted Aug 13, 2019·16 cites·16 claims
Showing the top 50 of 131 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →